OKYO Pharma Limited

OKYO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.35

+$0.02 (+1.50%)

At close: Sep 22, 2026, 4:00 PM ET

$1.33

-$0.02 (-1.48%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Key Executives

Name	Position
Robert J. Dempsey	Chief Executive Officer & Executive Director
Keeren Shah	Chief Financial Officer
Flavio Mantelli	Chief Medical Officer
Gary S. Jacob	Chief Development Officer & Director
Michael Paul Beck	Founder
Rajkumar Patil	Chief Scientific Officer

Latest SEC Filings

Date	Type	Title
Aug 07, 2026	20-F/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Aug 07, 2026	4/A	[Amend] Filing
Jul 29, 2026	4	Filing
Jul 29, 2026	3	Filing

View All SEC Filings ➞

OKYO Pharma Limited

Country	United Kingdom
IPO Date	May 16, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Robert J. Dempsey

Contact Details

35a Albemarle St London, GL W1S 4JE United Kingdom

https://www.okyopharma.com

44 20 7495 2379

Stock Details

Ticker Symbol	OKYO
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	0001849296
CUSIP Number	679345108
ISIN Number	GG00BMFG5F62
SIC Code	2836